Share:
Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx s existing bone franchise
Ultragenyx leads and funds development to approval; Mereo retains commercial rights in Europe, Ultragenyx commercializes in US and in rest of world
Mereo receives $50 million upfront and is eligible for milestones up to $254 million
NOVATO, Calif., LONDON, and REDWOOD CITY, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, and Mereo BioPharma Group plc (NASDAQ:MREO, AIM: MPH)), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced a license and collaboration agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta (OI). Setrusumab is an investigational anti-sclerostin fully human mono
川普簽署《外國公司問責法》!中企赴美上市面臨嚴格審計 | 全球
nownews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nownews.com Daily Mail and Mail on Sunday newspapers.
Equitrans Midstream Provides 2021 Guidance – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.